Altman Peter purchased $7K of BCDA
Altman Peter (President and CEO) purchased 7,500 shares of BioCardia, Inc. (BCDA) at an average of $0.96 ($0.90–$0.97) across 3 trades over 2026-07-08 to 2026-07-10.
How this was made
The 30-second read
Why it matters
The newest fact is the disclosed open-market purchase of 7,500 shares across three trades between 2026-07-08 and 2026-07-10, totaling $7,175.
Market read
Traders may view the filing as a small bullish sentiment datapoint, but it lacks fundamental catalysts and is unlikely to drive sustained repricing alone.
What to watch
The article notes no 10b5-1 plan and provides only transaction details, not rationale, timing constraints, or whether other insiders are buying/selling.
Background
This is an SEC Form 4 insider transaction for BioCardia, Inc., reported by CEO Peter Altman.
Ticker impact
BioCardia CEO Peter Altman filed a Form 4 open-market purchase of 7,500 shares at about $0.9567 weighted average.
Likely limited near-term impact; any effect is sentiment-driven and typically fades unless followed by larger disclosures.
The filing is a primary-source insider transaction, but the disclosed size ($7,175) is small and the article provides no new operational or financial information.
Market effects
No clear sector read-through from a small CEO open-market buy without accompanying company-specific fundamentals.
None indicated.
None indicated.
Counterpoint
Insider buys can be routine liquidity or diversification-related and do not necessarily reflect near-term business improvement.
Key entities
- issuerBioCardia, Inc.
Company whose CEO insider transaction is disclosed on Form 4.
- insiderAltman Peter
President and CEO reporting the open-market purchase.
